Enveric Biosciences reports positive IND‑enabling ADMET results for lead candidate EB‑003
Enveric Biosciences announced that its non‑hallucinogenic neuroplastogenic drug candidate EB‑003 passed a series of IND‑enabling in‑vitro ADMET studies. The tests, covering more than 70 assays, showed favorable intestinal absorption, low plasma protein binding, stability against liver enzymes and no significant inhibition of major metabolic enzymes or transporters. CEO Joseph Tucker said the data represent a key milestone and support moving the program toward a first‑in‑human trial.
Why it matters
The positive preclinical data strengthen EB‑003’s development profile, which could improve investor confidence and affect ENVB’s share price as the company moves closer to filing an IND. No new timeline was disclosed, so the impact will depend on future regulatory filings.
Key facts
- 1Enveric completed IND‑enabling ADMET studies for EB‑003 involving over 70 individual assays. investing.com
- 2The studies indicated favorable predicted intestinal absorption in human cell‑based permeability tests. finance.yahoo.com
- 3EB‑003 showed low plasma protein binding, suggesting favorable distribution and clearance. rttnews.com
- 4The compound was stable against liver metabolism enzymes from multiple species, including humans. rttnews.com
- 5EB‑003 did not significantly inhibit or induce major metabolic enzymes or multidrug transporter proteins. finance.yahoo.com
- 6Joseph Tucker, Director and CEO, said the results represent an important milestone toward a first‑in‑human trial. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.